PRECISION MEDICINE · GLENVIEW, ILLINOIS

Decoding the Biology of
Race, Ciliary Signaling,
and Inflammatory
Disease - Through AI/ML

McGenome LLC develops race-calibrated molecular diagnostic platforms for rare and complex diseases where existing tools systematically fail the patients who need them most. Three patent-pending platforms. One founding mission.

SarcoActivity™Patent Pending · US 63/078,909 · May 31 2026
KIF7-CilioPanel™Patent Pending · US 64/085,517
nmMLCK PlatformPatent Pending · US 64/085,517
NIH STTRPhase I Applications in Preparation · NHLBI · NIMHD · NICHD
Published ScienceAlafghani et al. · Human Genomics · 2026
Patent-Pending Platforms

Three Platforms. Three Unmet Needs.

Developed from 30 years of kinesin biology, ciliary signaling, and molecular genetics - translated into precision diagnostic and therapeutic tools for the patients most underserved by existing standards.

Sarcoidosis · Health Equity

SarcoActivity™

Race-Calibrated AI Sarcoidosis Monitoring Platform

Serum ACE monitoring fails African American sarcoidosis patients due to two independent mechanisms: the rs1799752 II genotype polymorphism and ACE inhibitor pharmacological suppression - producing false-reassuring results in the population with 14× higher sarcoidosis mortality. SarcoActivity™ is a 7-component AI/ML platform providing race-calibrated composite disease activity monitoring, endotype classification, and drug response prediction.

US PPA No. 63/078,909 · Filed May 31, 2026 · Patent Pending
Academic and clinical validation in diverse sarcoidosis cohorts
7 components · 16 patent claims · BFD · SAI · FPP · MOEC · DRPE · NBDP · CDSS
Explore SarcoActivity™ →
Pediatric Rare Disease · Ciliopathy

KIF7-CilioPanel™

Molecular Diagnostic Platform for JSRD Ciliopathy

Joubert Syndrome and Related Disorders (JSRD) is a rare autosomal recessive ciliopathy affecting consanguineous populations globally, with a confirmed genetic diagnosis in fewer than 60% of patients using current single-gene testing. KIF7-CilioPanel™ is an 11-gene tiered NGS diagnostic platform combining functional Hedgehog pathway assays and the JCiloScore™ machine learning composite for JSRD diagnosis, prognosis, and organ surveillance planning.

US PPA No. 64/085,517 · Filed June 8, 2026 · Patent Pending
Alafghani et al. · Human Genomics · 2026 · Scientific Foundation
Validation in consanguineous Middle Eastern JSRD cohorts
Explore KIF7-CilioPanel™ →
ARDS · Vascular Leak · Therapeutics

nmMLCK Platform

AI/ML Precision Therapeutics Platform for ARDS

Acute Respiratory Distress Syndrome (ARDS) is a highly lethal critical care syndrome with no approved targeted pharmacotherapies. McGenome’s nmMLCK platform target-silences the endothelial-specific non-muscle myosin light chain kinase isoform (MLCK-L) to prevent microvascular barrier failure, utilizing a Neural ODE Digital Twin, GNN-RL siNA generative design, and lung-targeted LNPs.

US PPA No. 64/085,517 · Filed June 6, 2026 · Patent Pending
African ancestry-specific MYLK variant (rs117565355, rs80145233) design
5 components · Neural ODE Twin · GNN siNA generative design · Lung LNP
Explore nmMLCK Platform →
30

Years of Published Science

Peer-reviewed research in Human Genomics, J Mol Biol, PNAS, DNA Research, J Cell Science, and Genomics - kinesin biology, ciliary signaling, and molecular genetics from C. elegans to human disease.

3

Patent-Pending Platforms

Three AI/ML molecular medicine platforms filed at USPTO in 2026 - SarcoActivity™ (US 63/078,909), KIF7-CilioPanel™ (US 64/085,517), and nmMLCK Platform (US 64/085,517) - addressing sarcoidosis health equity, rare ciliopathy, and critical care medicine.

3

NIH STTR Applications

Phase I STTR applications in preparation for NHLBI, NIMHD, and NICHD mechanisms, translating McGenome's patent-pending platforms into clinical realities.